#METABOLOMICS WORKBENCH DATATRACK_ID:3891 STUDY_ID:ST002583 ANALYSIS_ID:AN004254 VERSION 1 CREATED_ON 04-27-2023 #PROJECT PR:PROJECT_TITLE MoTrPAC PR:PROJECT_SUMMARY MoTrPAC is a national research consortium designed to discover and perform PR:PROJECT_SUMMARY preliminary characterization of the range of molecular transducers (the PR:PROJECT_SUMMARY "molecular map") that underlie the effects of physical activity in humans. The PR:PROJECT_SUMMARY program's goal is to study the molecular changes that occur during and after PR:PROJECT_SUMMARY exercise and ultimately to advance the understanding of how physical activity PR:PROJECT_SUMMARY improves and preserves health. Preclinical and clinical studies will examine the PR:PROJECT_SUMMARY systemic effects of endurance and resistance exercise across a range of ages and PR:PROJECT_SUMMARY fitness levels by molecular probing of multiple tissues before and after acute PR:PROJECT_SUMMARY and chronic exercise. This program is the largest targeted NIH investment of PR:PROJECT_SUMMARY funds into the mechanisms of how physical activity improves health and prevents PR:PROJECT_SUMMARY disease. The MoTrPAC program is supported by the NIH Common Fund and is managed PR:PROJECT_SUMMARY by a trans-agency working group representing multiple NIH institutes and PR:PROJECT_SUMMARY centers, led by the NIH Office of Strategic Coordination, National Institute of PR:PROJECT_SUMMARY Arthritis and Musculoskeletal and Skin Diseases, National Institute of Diabetes PR:PROJECT_SUMMARY and Digestive and Kidney Diseases, National Institute on Aging, and National PR:PROJECT_SUMMARY Institute of Biomedical Imaging and Bioengineering. MoTrPAC Steering Committee: PR:PROJECT_SUMMARY Wendy Kohrt, Chair, Russ Tracy, Co-Chair; NIH Program Manager, Concepcion PR:PROJECT_SUMMARY Nierras. Euan Ashley and Matthew Wheeler are the PIs for the Motrpac PR:PROJECT_SUMMARY Bioinformatics / Data Coordination Center. PR:INSTITUTE MoTrPAC PR:LAST_NAME Ashley PR:FIRST_NAME Euan PR:ADDRESS Falk Building CV267, 870 Quarry Road, Stanford, California 94305 PR:EMAIL motrpac-data-deposition@lists.stanford.edu PR:PHONE (650) 725-1846 PR:DOI http://dx.doi.org/10.21228/M8V97D #STUDY ST:STUDY_TITLE MoTrPAC: Endurance exercise training study in young adult rats, Rat Plasma - ST:STUDY_TITLE Targeted Tricarboxylic Acid Cycle ST:STUDY_SUMMARY The goal of the endurance exercise training study in young adult rats (internal ST:STUDY_SUMMARY code: PASS1B-06) was to perform exercise training studies in adult (6 month) ST:STUDY_SUMMARY F344 rats, and from these rats collect as many tissues as feasible in order to ST:STUDY_SUMMARY provide high quality samples for detailed analysis by chemical analysis sites. ST:STUDY_SUMMARY Tissues were collected from 10-12 rats sedentary control rats concurrent with ST:STUDY_SUMMARY the collection of the 8-week training groups. The 8-week training group and ST:STUDY_SUMMARY controls were from the same cohort and same age at euthanasia (either 8). For ST:STUDY_SUMMARY the older age group, an additional set of controls (n=5-6) were collected with ST:STUDY_SUMMARY the 1-2 week training group. Rats were either sedentary or underwent an exercise ST:STUDY_SUMMARY training program. Rats were exercised on the rodent treadmill 5 days per week ST:STUDY_SUMMARY using a progressive training protocol designed to exercise the rats at ST:STUDY_SUMMARY approximately 70% of VO2max as outlined in the Table on the next page. Training ST:STUDY_SUMMARY was performed no earlier than 10:00 am and no later than 5:00 pm over 5 ST:STUDY_SUMMARY consecutive days per week. Training was initiated with the treadmill set at 70% ST:STUDY_SUMMARY of VO2 max (see tables) and 5 degrees grade for 20 minutes. The duration of ST:STUDY_SUMMARY exercise was increased by one minute each day until day 31 of training (start of ST:STUDY_SUMMARY week 7), when a duration of 50 min was reached. Speed and grade of each training ST:STUDY_SUMMARY session increased in larger increments due to treadmill parameters. The highest ST:STUDY_SUMMARY intensity and duration of training began on day 31. This intensity was ST:STUDY_SUMMARY maintained for the final 10 days of the protocol to ensure steady state had been ST:STUDY_SUMMARY achieved. If any rats were unable to perform at least 4 days of training per ST:STUDY_SUMMARY week they were removed from the study and euthanized. It is important to note ST:STUDY_SUMMARY that the starting treadmill speed varied depending on the sex and age of the ST:STUDY_SUMMARY rat. The initial and maximum speeds were based on VO2max measurements obtained ST:STUDY_SUMMARY during the pre-training testing of the compliant rats. Rats assigned to the ST:STUDY_SUMMARY control group followed a schedule similar to the training group. They were ST:STUDY_SUMMARY placed in one lane on the treadmill for 15 minutes/day, 5 days per week. The ST:STUDY_SUMMARY treadmill was set at 0 m/min at an incline that corresponded to the incline ST:STUDY_SUMMARY being used by the training group. ST:INSTITUTE Mayo Clinic ST:DEPARTMENT Internal Medicine ST:LABORATORY Mayo Clinic Metabolomics Resource Core (MCMRC) ST:LAST_NAME Nair ST:FIRST_NAME K. Sreekumaran ST:ADDRESS 200 1st St SW, Rochester, MN 55902 ST:EMAIL nair@mayo.edu ST:PHONE (507) 284-2511 ST:SUBMIT_DATE 2023-04-25 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Rattus norvegicus SU:TAXONOMY_ID 10116 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS 1628FB23-6F66-47D4-8D82-63C87726F0FD 90245013110 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=16dec20_22.D.zip SUBJECT_SAMPLE_FACTORS 69FD4884-786D-4F2A-97B1-6174FBD25D60 90248013110 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=16dec20_23.D.zip SUBJECT_SAMPLE_FACTORS 07AF7369-F082-4CA7-99D5-D973F4A162C9 90252013110 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=16dec20_51.D.zip SUBJECT_SAMPLE_FACTORS F9BEE1FA-E2DB-4BE4-A79C-99D585D6FD17 90265013110 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=16dec20_29.D.zip SUBJECT_SAMPLE_FACTORS A77AC89A-1D9E-4516-9DA4-2BE99C8126EF 90266013110 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=16dec20_30.D.zip SUBJECT_SAMPLE_FACTORS BC49E4EF-E2FE-4269-BAF0-461F768BD95D 90217013110 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=16dec20_12.D.zip SUBJECT_SAMPLE_FACTORS 0559B193-BED3-4170-B045-10A2B6441CB6 90229013110 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=16dec20_18.D.zip SUBJECT_SAMPLE_FACTORS 90CFE5A4-76FE-4458-A2B1-A66F0B60118E 90232013110 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=16dec20_19.D.zip SUBJECT_SAMPLE_FACTORS F0D83B29-8EFA-4CDE-B1AA-2358AC220ECF 90237013110 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=16dec20_20.D.zip SUBJECT_SAMPLE_FACTORS FCE9ABE6-B60B-4934-BAE5-56AF8B11ECEC 90239013110 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=16dec20_21.D.zip SUBJECT_SAMPLE_FACTORS B73AB139-7210-4498-9CCF-E1DBE6EBA71C 90559013110 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=15dec20_33.D.zip SUBJECT_SAMPLE_FACTORS EA5C8932-9325-4DA5-96BB-50CD49CEDD10 90560013110 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=15dec20_34.D.zip SUBJECT_SAMPLE_FACTORS 0645F621-878C-4C9B-84A6-58862BAA17D9 90564013110 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=15dec20_35.D.zip SUBJECT_SAMPLE_FACTORS 68083256-8DAA-4185-B446-0CAF600474B5 90567013110 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=15dec20_36.D.zip SUBJECT_SAMPLE_FACTORS 6A013AA1-4D1E-4B75-B691-6BA22D928E51 90571013110 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=15dec20_37.D.zip SUBJECT_SAMPLE_FACTORS 6D680EA2-C62B-4A35-8B6E-2ED6A79CB017 90421013110 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=15dec20_23.D.zip SUBJECT_SAMPLE_FACTORS 53F914B0-FD4F-4340-84A6-48341EAB3798 90422013110 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=15dec20_24.D.zip SUBJECT_SAMPLE_FACTORS D350D633-8D95-4783-99F2-BB8294D2EC32 90423013110 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=15dec20_25.D.zip SUBJECT_SAMPLE_FACTORS 0DBFEB04-1B58-43CF-BAFD-9AA9915B67F6 90426013110 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=15dec20_26.D.zip SUBJECT_SAMPLE_FACTORS 10E282EB-1DBA-406E-BD5D-81027083A01D 90430013110 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=15dec20_27.D.zip SUBJECT_SAMPLE_FACTORS B137E81D-A9DE-4E3A-8E2B-AD6C22920B7E 90576013110 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=15dec20_38.D.zip SUBJECT_SAMPLE_FACTORS DC8B35E8-4AA8-4829-8569-F223D069620C 90578013110 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=15dec20_39.D.zip SUBJECT_SAMPLE_FACTORS 8904857C-2073-4BBA-AC7C-1EC239E5BFF7 90581013110 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=15dec20_40.D.zip SUBJECT_SAMPLE_FACTORS 1F9BD644-303F-43E7-94BE-FF6654306F5E 90585013110 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=15dec20_41.D.zip SUBJECT_SAMPLE_FACTORS 0409BED3-F9FE-4C06-9920-74F5E5CA04A3 90587013110 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=15dec20_42.D.zip SUBJECT_SAMPLE_FACTORS 4E974304-21EB-42E8-A729-A7FB6B406E64 90439013110 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=15dec20_28.D.zip SUBJECT_SAMPLE_FACTORS 6527EC12-E7EB-4F17-BF0A-0AC7CD1819A0 90441013110 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=15dec20_29.D.zip SUBJECT_SAMPLE_FACTORS AEB1611A-F29E-43F8-B9F3-A2BC4F9EB504 90444013110 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=15dec20_30.D.zip SUBJECT_SAMPLE_FACTORS FDA87A8D-3634-4C42-9A1A-0EA03B58BB01 90449013110 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=15dec20_31.D.zip SUBJECT_SAMPLE_FACTORS CDCFA3F1-07ED-4737-A36D-15EFEC325AA5 90450013110 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=15dec20_32.D.zip SUBJECT_SAMPLE_FACTORS 2E37478F-525F-4E5E-A882-EE75FD0CFB29 90406013110 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=15dec20_18.D.zip SUBJECT_SAMPLE_FACTORS A9CE3E3D-31A0-4443-8A7F-8FD831D79248 90410013110 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=15dec20_19.D.zip SUBJECT_SAMPLE_FACTORS 3D5BC47C-BB3D-45A2-8DB8-D7ADCD51997C 90412013110 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=15dec20_20.D.zip SUBJECT_SAMPLE_FACTORS 89D6F615-D17C-4EB9-88EB-A602940FF179 90416013110 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=15dec20_21.D.zip SUBJECT_SAMPLE_FACTORS FE012DC0-AF32-4C70-A4D4-F042B8BC4EC6 90420013110 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=15dec20_22.D.zip SUBJECT_SAMPLE_FACTORS 22D700B9-EDD0-4BC8-8155-EB9C39417F81 90280013110 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=16dec20_32.D.zip SUBJECT_SAMPLE_FACTORS 1CA4210C-3CE6-4A5A-996B-673EBDEB3B81 90281013110 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=16dec20_33.D.zip SUBJECT_SAMPLE_FACTORS 9F3E1040-D409-421E-B635-2572DC20ED89 90283013110 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=16dec20_34.D.zip SUBJECT_SAMPLE_FACTORS 569A9229-04E8-414A-A195-FE9E8F1B66AB 90289013110 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=16dec20_35.D.zip SUBJECT_SAMPLE_FACTORS E4271AF1-899A-4A65-9D8D-BF18CEE3F1CF 90292013110 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=16dec20_36.D.zip SUBJECT_SAMPLE_FACTORS 0D5071F5-D166-4CF1-BE8B-EB4DF6E04C0E 90251013110 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=16dec20_24.D.zip SUBJECT_SAMPLE_FACTORS 2479BEE5-2A38-4D09-B15B-B1715F561A9F 90254013110 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=16dec20_26.D.zip SUBJECT_SAMPLE_FACTORS 0A4A7935-3AF4-463F-84E3-DCF07671509D 90258013110 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=16dec20_52.D.zip SUBJECT_SAMPLE_FACTORS 04C84D7E-FC8C-422F-AE4B-CAFADB63407B 90259013110 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=16dec20_28.D.zip SUBJECT_SAMPLE_FACTORS 2B969165-1A52-43AA-8FD9-39AFA62F094F 90267013110 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=16dec20_31.D.zip SUBJECT_SAMPLE_FACTORS 0BD282C7-7832-4581-9089-08A32D557034 90218013110 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=16dec20_13.D.zip SUBJECT_SAMPLE_FACTORS 955498F4-70A0-4D50-A2BA-619A8FED8FEF 90222013110 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=16dec20_14.D.zip SUBJECT_SAMPLE_FACTORS CFE06932-9314-4BCC-B2D9-73883D5FCDFB 90223013110 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=16dec20_15.D.zip SUBJECT_SAMPLE_FACTORS 3719CB62-B551-49BE-94A0-E51DFE13D30D 90225013110 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=16dec20_16.D.zip SUBJECT_SAMPLE_FACTORS F65955CE-E49F-48C7-B861-02A2FDF6F9B8 90227013110 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=16dec20_17.D.zip #COLLECTION CO:SAMPLE_TYPE Plasma #TREATMENT TR:TREATMENT_SUMMARY - #SAMPLEPREP SP:SAMPLEPREP_SUMMARY homogenized in PBS, isotope IS added, deproteinized, 2 steps derivatization with SP:SAMPLEPREP_SUMMARY ethoxamine, MTBSTFA #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY Analytes were chromatographically separated with 17 minutes GC gradient CH:INSTRUMENT_NAME Agilent Intuvo 9000 GC CH:COLUMN_NAME Agilent HP-5MS (30m x 0.250mm, 0.25um) CH:CHROMATOGRAPHY_TYPE GC #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME Agilent 5977B HES MSD MS:INSTRUMENT_TYPE Single quadrupole MS:MS_TYPE EI MS:MS_COMMENTS SIM; peak integration, concentrations calculated MS:ION_MODE POSITIVE #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS micromolar MS_METABOLITE_DATA_START Samples 90245013110 90248013110 90252013110 90265013110 90266013110 90217013110 90229013110 90232013110 90237013110 90239013110 90559013110 90560013110 90564013110 90567013110 90571013110 90421013110 90422013110 90423013110 90426013110 90430013110 90576013110 90578013110 90581013110 90585013110 90587013110 90439013110 90441013110 90444013110 90449013110 90450013110 90406013110 90410013110 90412013110 90416013110 90420013110 90280013110 90281013110 90283013110 90289013110 90292013110 90251013110 90254013110 90258013110 90259013110 90267013110 90218013110 90222013110 90223013110 90225013110 90227013110 Factors Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male 2-Hydroxyglutarate 2.7660 1.8320 2.0220 1.5320 2.2680 2.8100 1.1660 1.1280 2.1020 1.2840 1.3160 1.2360 1.7280 1.8280 1.0440 1.0540 0.9140 1.0600 1.4640 1.5820 1.5080 2.7840 1.8440 1.7420 2.1360 1.7940 1.0920 1.5600 1.3400 1.4720 1.3900 1.1160 1.3580 1.6480 1.4080 1.3920 1.6680 1.9540 2.1020 1.7960 1.5400 2.0120 2.0640 1.1480 1.7660 0.8260 1.3400 3.4060 1.3440 0.9640 Aspartate 4.0900 3.4620 3.2600 3.5100 9.6700 5.5140 4.0220 4.3980 14.8900 4.0040 5.5640 5.2120 7.1240 7.1720 8.7100 7.0220 5.4220 5.4620 6.3540 5.1260 6.5280 23.0360 6.5740 13.6040 8.2760 9.8900 6.6880 12.4020 7.5240 10.7960 5.9240 8.1440 6.5860 6.0960 9.9620 4.5420 11.9040 7.0120 4.0420 8.4840 3.2840 5.0520 4.3460 4.0700 6.1560 6.7180 5.0540 5.4480 3.5720 2.8480 cis-aconitate 5.6800 3.7240 3.5000 4.7880 5.0800 4.4160 3.7380 3.5160 3.9320 3.9540 4.2500 4.0320 4.6380 4.7920 5.0260 4.5640 3.7200 4.5300 4.1580 3.3220 4.3600 5.5960 4.4800 4.8580 4.8820 3.2160 3.9640 4.0800 4.3120 4.9000 3.1180 2.0600 3.5900 3.7580 3.6780 4.1280 4.5020 4.2840 4.7240 4.5600 3.8400 5.0680 3.7900 5.6540 4.6400 2.5180 3.1720 5.0200 3.3220 3.9460 Citrate 225.4900 210.4900 232.7520 172.6260 214.2380 174.5000 166.2940 158.5760 198.6440 154.0340 187.7040 174.0960 200.4100 214.2380 194.4260 176.5640 159.9080 160.0960 170.4200 154.6460 183.6020 247.6260 201.7780 199.0700 196.5320 147.4200 155.1100 181.7060 167.1100 169.9180 171.5200 115.5320 158.9720 172.4880 177.5720 146.6000 147.6360 171.8860 177.1840 168.4140 199.0600 203.9340 190.8520 165.0460 178.4300 120.1520 131.7580 142.4960 130.7100 127.5680 Fumarate 7.1860 3.8200 7.9200 4.1680 4.1060 6.8000 4.0080 3.0960 4.8200 3.4600 3.7460 2.3940 2.9060 3.4520 3.0300 2.9460 2.6480 2.9460 3.2860 3.1100 3.4940 5.1100 2.9740 3.3840 3.4860 3.1180 3.0180 3.6140 3.4920 3.0600 2.8020 2.1100 3.7700 3.4100 3.5660 3.7080 3.3540 3.6680 4.8900 4.3280 4.2320 4.2300 6.8900 3.2260 4.0300 3.9120 3.5520 6.3040 3.2600 2.8620 Glutamate 57.0500 54.7060 45.9340 58.9840 73.8800 80.7760 71.2100 79.5640 98.3060 73.7480 52.4560 59.4120 60.5440 60.0440 52.7920 73.7760 72.6500 56.4580 62.0920 72.5680 50.5660 98.1840 56.5140 67.0200 57.4540 68.4160 67.2560 90.0740 56.5780 94.6560 49.8300 43.6280 64.3660 57.2660 59.5160 62.6920 67.9480 72.2480 72.0320 87.1480 46.7540 74.0740 54.3420 61.8140 67.5700 52.7940 63.3780 61.3820 55.1440 37.6200 Isocitrate 5.3200 5.0640 3.9560 3.8160 7.0280 2.7060 3.5020 2.9000 3.8180 3.4860 4.2940 2.6480 4.9520 4.2860 5.7720 4.3760 1.8660 3.3420 3.1940 2.5860 4.5120 6.7220 4.1980 5.1580 5.7620 2.2520 2.2600 3.1240 3.4120 3.9900 2.9640 3.6620 3.9040 3.1600 4.4880 3.8860 3.4020 4.1860 3.8460 3.1640 3.9960 4.5680 2.3280 4.6720 4.1960 1.6080 2.1340 3.5920 2.4800 2.6500 Ketoglutarate 23.6760 16.5420 18.9520 16.3980 15.1580 17.2560 18.4600 16.4740 19.2060 18.6560 14.9360 11.6260 15.8900 15.0380 14.8600 17.6340 14.6140 14.6780 15.1400 17.3520 14.1880 15.4760 14.5300 14.0600 15.1580 12.8040 15.8960 15.7340 19.0680 18.3280 12.0180 8.2360 17.9320 14.6980 14.2120 15.6200 12.1000 16.8360 17.9280 14.9580 15.0300 17.1900 15.2460 13.7840 15.4700 10.7800 16.3420 16.4600 15.3080 14.6880 Lactate 1284.9200 1070.3880 1023.4600 1267.5260 1182.4140 841.7760 1572.6320 926.2680 1246.9220 1085.7200 1047.3000 959.5320 920.9320 888.2260 1003.9680 852.2300 896.1980 1110.6860 973.9140 1080.9120 1088.8760 1019.2980 1066.4820 1050.8620 952.7820 960.4600 1002.4320 985.4820 1332.4280 1029.3620 911.9960 605.1800 1269.7220 1051.4200 1076.6320 1367.9260 1349.0820 1144.1040 1046.4820 933.5340 1184.1500 1046.7960 1242.9320 1151.4900 1173.6140 893.3860 1194.2760 1125.5240 1050.3800 1289.7780 Malate 17.9540 11.4340 14.1600 11.4620 11.8560 9.8400 12.2140 7.4680 14.2420 9.1380 10.1080 6.4120 9.5160 10.3900 9.2020 8.6360 5.6760 7.3580 7.4560 7.5380 8.8260 13.6560 8.7060 9.9620 9.8520 6.8940 7.8980 8.3780 11.9480 8.5560 7.5160 5.9260 11.4740 9.6820 10.7080 8.8480 7.9180 10.0560 8.6140 8.5900 14.3020 11.4760 12.7580 9.2840 11.7080 28.1120 10.8000 11.2380 8.2080 8.4560 Oxaloacetate 0.7800 0.6540 3.6960 0.2740 0.4340 2.6860 0.7740 0.8200 1.1020 0.7120 0.5920 0.7540 0.5900 0.6440 0.6100 0.8040 0.8080 1.0940 1.1080 0.9180 0.6980 0.7940 0.7180 0.4660 0.6100 0.8980 0.7300 0.7920 0.8280 0.5700 1.5080 1.0020 1.2240 1.4420 0.8840 0.4440 0.4660 0.3680 0.4120 0.4920 0.5740 0.9880 2.0340 0.3420 0.3120 1.9740 1.9340 1.9480 1.1260 0.9420 Succinate 6.1940 3.8620 7.6580 4.1540 7.2200 6.2540 3.5080 2.9740 8.4880 3.9820 3.6160 2.7340 3.0360 3.3020 3.1600 3.6260 2.9100 3.7680 4.3400 3.9320 3.6520 7.5340 3.0240 4.5800 3.3020 3.8780 4.2740 5.1380 4.6160 3.4580 2.4400 3.2620 3.5660 3.6220 5.9400 4.1900 6.4580 4.9160 4.6940 4.3320 4.3280 3.9920 5.1520 3.2740 4.8820 2.4760 3.0580 6.8700 3.1100 2.7600 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name pubchem_id inchi_key kegg_id other_id other_id_type ri ri_type moverz_quant 2-Hydroxyglutarate 9.98 433 Aspartate 9.37 418 cis-aconitate 14.08 459 Citrate 14.09 591 Fumarate 6.13 287 Glutamate 10.58 432 Isocitrate 14.09 591 Ketoglutarate 8.37 360 Lactate 4.18 261 Malate 8.93 419 Oxaloacetate 8.37 346 Succinate 5.19 289 METABOLITES_END #END